buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Neuland Laboratories Limited
03 /Listed universe · Healthcare · CDMO

Neuland Laboratories Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · CDMO

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Market cap
₹28,905 cr
P/E (TTM)
58.5
P/B (latest)
15.4
ROE (TTM)
19.4%
ROCE (TTM)
23.1%
Sales CAGR 3y
19.3%
PAT CAGR 3y
30.6%
Debt / equity
0.1x
Promoter
32.6%
Dividend yield
0.15%
Size
Small
Codes
NEULANDLAB · 524558
Price

₹21,440 · 28 Sept 2026

1M
−7.6%
3M
+19.4%
6M
+77.7%
YTD
+42.4%
1Y
+53.5%
3Y
+464.5%
5Y
—
vs 52w high
−10.6%

52-week ₹11,555 – ₹23,995 · ADTV ₹138.1 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ